CN106620435A - Traditional Chinese medicine composition for treating gouty arthritis and application thereof - Google Patents
Traditional Chinese medicine composition for treating gouty arthritis and application thereof Download PDFInfo
- Publication number
- CN106620435A CN106620435A CN201710185916.2A CN201710185916A CN106620435A CN 106620435 A CN106620435 A CN 106620435A CN 201710185916 A CN201710185916 A CN 201710185916A CN 106620435 A CN106620435 A CN 106620435A
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- medicine composition
- urarthritis
- traditional chinese
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/21—Amaranthaceae (Amaranth family), e.g. pigweed, rockwort or globe amaranth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
- A61K36/355—Lonicera (honeysuckle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/486—Millettia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/68—Plantaginaceae (Plantain Family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/708—Rheum (rhubarb)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K36/718—Coptis (goldthread)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/734—Crataegus (hawthorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
- A61K36/748—Oldenlandia or Hedyotis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/894—Dioscoreaceae (Yam family)
- A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
- A61K36/8994—Coix (Job's tears)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/90—Smilacaceae (Catbrier family), e.g. greenbrier or sarsaparilla
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
Abstract
The invention provides a traditional Chinese medicine composition for treating gouty arthritis and application thereof, and relates to the technical field of traditional Chinese medicines. The traditional Chinese medicine composition for treating the gouty arthritis is prepared from the following raw material components of rhizoma atractylodis, bighead atractylodes rhizome, rhizoma smilax china, rhizoma dioscoreae, coix seed, radix achyranthis bidentatae, root of flemingia philippinensis, caulis spatholobi, radix paeoniae rubra, herb of oldenlandia diffusa, rheum officinale, rhizoma coptidis, honeysuckle stem, semen plantaginis, semen brassicae, fructus crataegi, rhizoma smilacis glabrae and common fenugreek seed. The invention also provides the application of the traditional Chinese medicine composition for treating the gouty arthritis. The traditional Chinese medicine composition has the advantages that the gouty arthritis can be effectively treated, the medicine mechanism is clear, the medicine effect is good, the side effect is little, the cost is low, and the obvious practicality and market value are realized.
Description
Technical field
The present invention relates to the field of Chinese medicines, more particularly, to a kind of Chinese medicine composition for treating urarthritis and its should
With.
Background technology
Urarthritis is one kind because purine metabolism product monosodium urate salt (monosodium urate, MSU) exists
It is supersaturated in extracellular fluid and is deposited in the disease caused in tissue, caused by purine metabolic disturbance and (or) underexcretion
Hyperuricemia it is directly related, main clinical manifestation is：Acute arthritis phase, tophus and chornic arthritis phase etc..Gout
Property arthritis be apt to occur in middle-aged male, be more common in Metatarsophalangeal joint, also can betide other compared with large joint, especially foot with
Ankle joint.
The pathogenesis of urarthritis is sufficiently complex, at present it is generally believed that monosodium urate salt in joint
(monosodium urate, MSU) concentration is supersaturated to form crystallization deposition, causes joint and surrounding tissue to be inflamed reaction,
It is the main cause of urarthritis formation.It has now been found that, monocyte is close with the outbreak relation of urarthritis
Cut, when urarthritis is shown effect, monocytic Inflammatory Pathway is activated, cytokine profiles such as IL-1 β and TNF-α
Expression can rise, so as to cause the various symptoms of urarthritis.
Urarthritis can result in having an intense pain for patient articular, and serious threat patient's is healthy, greatly
Have impact on the quality of life of patient.At present, the medicine for treating urarthritis mostly is Western medicine, there is large side effects, price and holds high
Your the problems such as, additionally, still there are some Chinese medicines for treating urarthritis, but lack system in-depth study.Therefore, just need
From the traditional theory of traditional Chinese medical science of China, the Chinese medicine composition of effectively treatment urarthritis is developed.
Therefore, it is special to propose the present invention.
The content of the invention
It is an object of the invention to provide a kind of Chinese medicine composition for treating urarthritis.
The invention provides a kind of Chinese medicine composition for treating urarthritis, the preparing raw material of the Chinese medicine composition
Including following component：
Rhizoma atractylodis, the bighead atractylodes rhizome, chinaroot greenbrier, Chinese yam, coix seed, radix achyranthis bidentatae, waras, reticulate millettia, the radix paeoniae rubrathe, oldenlandia diffusa, rheum officinale,
The coptis, caulis lonicerae, plantain seed, semen brassicae, hawthorn, smilax and faenum graecum.
Further, in parts by weight, the preparing raw material of the Chinese medicine composition is made up of following component：
Rhizoma atractylodis 8-16 parts, bighead atractylodes rhizome 11-19 parts, chinaroot greenbrier 21-29 parts, Chinese yam 8-16 parts, coix seed 26-34 parts, radix achyranthis bidentatae 8-
16 parts, waras 21-29 part, reticulate millettia 26-34 parts, radix paeoniae rubrathe 11-19 parts, oldenlandia diffusa 26-34 parts, rheum officinale 2-10 parts are yellow
Even 8-16 parts, caulis lonicerae 16-24 parts, plantain seed 8-16 parts, semen brassicae 8-16 parts, hawthorn 8-16 parts, smilax 26-34 parts and
Faenum graecum 16-24 parts.
Further, in parts by weight, the preparing raw material of the Chinese medicine composition is made up of following component：
Rhizoma atractylodis 10-14 parts, bighead atractylodes rhizome 13-17 parts, chinaroot greenbrier 23-27 parts, Chinese yam 10-14 parts, coix seed 28-32 parts, radix achyranthis bidentatae
10-14 parts, waras 23-27 part, reticulate millettia 28-32 parts, radix paeoniae rubrathe 13-17 parts, oldenlandia diffusa 28-32 parts, rheum officinale 4-8 parts,
Coptis 10-14 parts, caulis lonicerae 18-22 parts, plantain seed 10-14 parts, semen brassicae 10-14 parts, hawthorn 10-14 parts, smilax 28-32
Part and faenum graecum 18-22 parts.
Further, in parts by weight, the preparing raw material of the Chinese medicine composition is made up of following component：
12 parts of rhizoma atractylodis, 15 parts of the bighead atractylodes rhizome, 25 parts of chinaroot greenbrier, 12 parts of Chinese yam, 30 parts of coix seed, 12 parts of radix achyranthis bidentatae, 25 parts of waras,
30 parts of reticulate millettia, 15 parts of the radix paeoniae rubrathe, 30 parts of oldenlandia diffusa, 6 parts of rheum officinale, 12 parts of the coptis, 20 parts of caulis lonicerae, 12 parts of plantain seed, in vain
20 parts of 12 parts of mustard seed, 12 parts of hawthorn, 30 parts of smilax and faenum graecum.
Further object is that providing a kind of application of the Chinese medicine composition.
The invention provides application of the Chinese medicine composition in treatment urarthritis medicine is prepared.
Further, the urarthritis is acute gouty arthritis.
Further, the formulation of the treatment urarthritis medicine is decoction.
Further, the occupation mode of the decoction is oral.
Further, the preparation method of the decoction is：By the various raw material soakings of Chinese medicine composition, subsequently decoct.
Further, the soak time is 30min, and the decocting time is 1h.
The Chinese medicine composition that the present invention is provided can effectively treat urarthritis, and clearly, drug effect is good for its pharmacology,
It is with strong points.
Description of the drawings
In order to be illustrated more clearly that the specific embodiment of the invention or technical scheme of the prior art, below will be to concrete
The accompanying drawing to be used needed for embodiment or description of the prior art is briefly described, it should be apparent that, in describing below
Accompanying drawing is some embodiments of the present invention, for those of ordinary skill in the art, before creative work is not paid
Put, can be with according to these other accompanying drawings of accompanying drawings acquisition.
Fig. 1 is the cell confirmatory experiment datagram of traditional Chinese medicine composition for treating urarthritis；
Fig. 2 is the cell confirmatory experiment datagram of traditional Chinese medicine composition for treating urarthritis；
Fig. 3 is the cell confirmatory experiment datagram of traditional Chinese medicine composition for treating urarthritis；
Fig. 4 is the cell confirmatory experiment datagram of traditional Chinese medicine composition for treating urarthritis；
Fig. 5 is the animal confirmatory experiment datagram of traditional Chinese medicine composition for treating urarthritis；
Fig. 6 is the animal confirmatory experiment datagram of traditional Chinese medicine composition for treating urarthritis.
Specific embodiment
Technical scheme is clearly and completely described below in conjunction with accompanying drawing, it is clear that described enforcement
Example is a part of embodiment of the invention, rather than the embodiment of whole.Based on the embodiment in the present invention, ordinary skill
The every other embodiment that personnel are obtained under the premise of creative work is not made, belongs to the scope of protection of the invention.
The invention provides a kind of Chinese medicine composition, its preparing raw material includes following component：Rhizoma atractylodis, the bighead atractylodes rhizome, chinaroot greenbrier, mountain
Medicine, coix seed, radix achyranthis bidentatae, waras, reticulate millettia, the radix paeoniae rubrathe, oldenlandia diffusa, rheum officinale, the coptis, caulis lonicerae, plantain seed, sinapsis alba
Son, hawthorn, smilax and faenum graecum.
In parts by weight, the preparing raw material of Chinese medicine composition includes following component：
Rhizoma atractylodis 8-16 parts, for example, can be 8,9,10,11,12,13,14,15 or 16 parts；Bighead atractylodes rhizome 11-19 parts, for example may be used
Think 11,12,13,14,15,16,17,18 or 19 parts；Chinaroot greenbrier 21-29 parts, for example can for 21,22,23,24,25,26,
27th, 28 or 29 parts；Chinese yam 8-16 parts, for example, can be 8,9,10,11,12,13,14,15 or 16 parts；Coix seed 26-34
Part, for example can be 26,27,28,29,30,31,32,33 or 34 parts；Radix achyranthis bidentatae 8-16 parts, for example can for 8,9,10,
11st, 12,13,14,15 or 16 parts；Waras 21-29 part, for example, can be 21,22,23,24,25,26,27,28 or 29
Part；Reticulate millettia 26-34 parts, for example, can be 26,27,28,29,30,31,32,33 or 34 parts；Radix paeoniae rubrathe 11-19 parts, for example may be used
Think 11,12,13,14,15,16,17,18 or 19 parts；Oldenlandia diffusa 26-34 parts, for example can for 26,27,28,29,
30th, 31,32,33 or 34 parts；Rheum officinale 2-10 parts, for example, can be 2,3,4,5,6,7,8,9 or 10 parts；Coptis 8-16 parts,
It for example can be 8,9,10,11,12,13,14,15 or 16 parts；Caulis lonicerae 16-24 parts, for example can for 16,17,18,19,
20th, 21,22,23 or 24 parts；Plantain seed 8-16 parts, for example, can be 8,9,10,11,12,13,14,15 or 16 parts；Sinapsis alba
Sub- 8-16 parts, for example, can be 8,9,10,11,12,13,14,15 or 16 parts；Hawthorn 8-16 parts, for example can for 8,9,10,
11st, 12,13,14,15 or 16 parts；Smilax 26-34 parts, for example, can be 26,27,28,29,30,31,32,33 or 34
Part；Faenum graecum 16-24 parts, for example, can be 16,17,18,19,20,21,22,23 or 24 parts.
The Chinese medicine composition that the present invention is provided, being capable of effectively treatment urarthritis.
In addition, present invention also offers application of the Chinese medicine composition in treatment urarthritis medicine is prepared.
In one preferred embodiment, the formulation for treating urarthritis medicine is decoction.
Another preferred embodiment in, treat urarthritis medicine formulation be paste.
In the Chinese medicine composition that the present invention is provided, the pharmacological action of each raw material is as follows：
Rhizoma atractylodis：Taste is pungent, hardship, it is warm in nature.Returns spleen, stomach, Liver Channel.It is drying damp and strengthening spleen, expelling wind and clearing away cold, improving eyesight.
The bighead atractylodes rhizome：Sweet, hardship, it is warm in nature.Returns spleen, stomach.Strengthening the spleen and replenishing qi, eliminate dampness and have diuretic effect, hidroschesis is antiabortive.
Chinaroot greenbrier：It is sweet, it is warm in nature.Return liver and kidney channel.Wines used as antirheumatic, diuresis, detumescence poison.
Chinese yam：It is sweet, it is mild-natured.Returns spleen, lung, kidney channel.Tonifying spleen nourishing the stomach, engender liquid and benefic lung, the puckery essence of kidney tonifying.
Coix seed：It is sweet, light, it is cool in nature.Returns spleen, stomach, lung channel.Invigorating the spleen excreting dampness, clearing away heat and eliminating pus, except numbness, Li Shui.
Radix achyranthis bidentatae：Bitter, sweet, acid, it is mild-natured.Return liver and kidney channel.Dispelling stasis of blood and stimulating the menstrual flow, filling liver kidney, strengthening the bones and muscles, inducing diuresis for treating strangurtia draws blood
It is descending.
Waras：It is sweet, slightly warm in nature, flat.Return lung, kidney, bladder warp.Wines used as antirheumatic, strong waist and knee.
Reticulate millettia：Bitter, micro-sweet, it is warm in nature.Return liver and kidney channel.Activate blood and relax tendons, nourishing blood for regulating menstruation.
The radix paeoniae rubrathe：Bitter, cold nature.Return liver warp.Clearing heat and cooling blood, blood stasis removing analgesic.
Oldenlandia diffusa：It is sweet, light, it is cool in nature.Return stomach, large intestine, small intestinl channel.It is clearing heat and detoxicating, inducing diuresis to remove edema, promoting blood circulation and stopping pain.
Rheum officinale：Bitter, it is cold in nature.Returns spleen, stomach, large intestine, liver, pericardium channel.Heat and toxic materials clearing away, clearing heat-fire, removing pattogenic heat from the blood and toxic material from the body, by the stasis of blood
Stimulate the menstrual flow, removing dampness through diuresis and removing jaundice.
The coptis：Bitter, it is cold in nature.The thoughts of returning home, spleen, stomach, courage, large intestine channel.Heat-clearing and damp-drying drug, purging intense heat and detonicating.
Caulis lonicerae：It is sweet, it is cold in nature.Attach to the lung and stomach meridians.It is clearing heat and detoxicating, dispelling wind dredging collateral.
Plantain seed：It is sweet, cold nature.Return kidney, bladder warp.Li Shui, heat-clearing, improving eyesight, eliminating the phlegm.
Semen brassicae：It is taste is pungent, warm in nature.Attach to the lung and stomach meridians.Warm lung slit phlegm profit gas, dissipating bind is removed obstruction in channels to relieve pain.
Hawthorn：Taste is sour, sweet, slightly warm in nature.Returns spleen, stomach, Liver Channel.Digestion gathered food, scattered blood stasis, expelling tenia.
Smilax：It is sweet, light, it is mild-natured.Return liver, stomach.Removing toxic substances, dehumidifying is easing joint movement.
Faenum graecum：Bitter, it is warm in nature.Return kidney channel.Warm kidney, dispelling cold, pain relieving.
Understand the present invention in order to clearer, be described in detail as follows in conjunction with specific embodiment.
Embodiment 1
A kind of decoction for treating urarthritis：Rhizoma atractylodis 12g, bighead atractylodes rhizome 15g, chinaroot greenbrier 25g, Chinese yam 12g, coix seed 30g,
Radix achyranthis bidentatae 12g, waras 25g, reticulate millettia 30g, radix paeoniae rubrathe 15g, oldenlandia diffusa 30g, rheum officinale 6g, coptis 12g, caulis lonicerae 20g,
Plantain seed 12g, semen brassicae 12g, hawthorn 12g, smilax 30g and faenum graecum 20g.
Preparation method：The various raw materials of above-mentioned Chinese medicine composition are soaked into 30min in water, first decocts water consumption to be higher by
Powder is degree, is decocted after boiling 30 minutes, and the second pan-fried amount of water is the first pan-fried 1/2, decoction 30 minutes after boiling, twice decocting liquid
The net mixing of filter of removing slag.
Embodiment 2
A kind of decoction for treating urarthritis：Rhizoma atractylodis 10g, bighead atractylodes rhizome 13g, chinaroot greenbrier 23g, Chinese yam 10g, coix seed 28g,
Radix achyranthis bidentatae 10g, waras 23g, reticulate millettia 28g, radix paeoniae rubrathe 13g, oldenlandia diffusa 28g, rheum officinale 4g, coptis 10g, caulis lonicerae 18g,
Plantain seed 10g, semen brassicae 10g, hawthorn 10g, smilax 28g and faenum graecum 18g.
Preparation method：The various raw materials of above-mentioned Chinese medicine composition are soaked into 30min in water, first decocts water consumption to be higher by
Powder is degree, is decocted after boiling 30 minutes, and the second pan-fried amount of water is the first pan-fried 1/2, decoction 30 minutes after boiling, twice decocting liquid
The net mixing of filter of removing slag.
Embodiment 3
A kind of decoction for treating urarthritis：Rhizoma atractylodis 14g, bighead atractylodes rhizome 17g, chinaroot greenbrier 27g, Chinese yam 14g, coix seed 32g,
Radix achyranthis bidentatae 14g, waras 27g, reticulate millettia 32g, radix paeoniae rubrathe 17g, oldenlandia diffusa 32g, rheum officinale 8g, coptis 14g, caulis lonicerae 22g,
Plantain seed 14g, semen brassicae 14g, hawthorn 14g, smilax 32g and faenum graecum 22g.
Preparation method：The various raw materials of above-mentioned Chinese medicine composition are soaked into 30min in water, first decocts water consumption to be higher by
Powder is degree, is decocted after boiling 30 minutes, and the second pan-fried amount of water is the first pan-fried 1/2, decoction 30 minutes after boiling, twice decocting liquid
The net mixing of filter of removing slag.
In order to contribute to the treatment principle of the sufficiently Chinese medicine composition that the explanation present invention is provided, in conjunction with specific experiment
It is described in detail as follows.
It should be noted that as do not explicitly pointed out, reagent, instrument or the equipment mentioned in this experimental example is conventional
Reagent, instrument or equipment, used method is conventional method.
The cell confirmatory experiment of traditional Chinese medicine composition for treating urarthritis
(1) material and reagent
Rat：SPF level Wistar rats, male, 220-250g.Purchased from disease prevention and control center of Henan Province.
THP-1 cells：Person monocytic cell.Given in preclinical medicine institute of Zhengzhou University siberian crabapple.
RPMI-1640 culture mediums：Purchased from Thermo Fisher Scientific companies.
FBS：Purchased from Chinese holly biological engineering material Co., Ltd.
Complete medium：10%FBS, 90%RPMI-1640 culture medium.
PMA：Phorbol exters, purchased from Sigma-Aldrich companies.
100ng/mL PMA：PMA is diluted with complete medium, to final concentration of 100ng/mL.
Uric acid sodium salt：Purchased from Sigma-Aldrich companies.
100 μ g/mL MSU solution：Uric acid sodium salt is dissolved to into 25mg/mL with 1M NaOH, complete medium is added, it is dilute
It is 100 μ g/ml to release to concentration, is placed one week in 4 DEG C of refrigerators so as to form MSU crystal.
200 μ g/mL MSU solution：Uric acid sodium salt is dissolved to into 25mg/mL with 1M NaOH, complete medium is added, it is dilute
It is 200 μ g/ml to release to concentration, is placed one week in 4 DEG C of refrigerators so as to form MSU crystal.
MSD liquids：The liquid of the Chinese medicine composition that the present invention is provided, decocts liquid, by liquid according to the mode of embodiment 1
Concentrated with Rotary Evaporators standby.
IL-1 β ELISA kits：Purchased from Abcam companies.
TNF-α ELISA kit：Purchased from Abcam companies.
(2) MSD Contained Serums are prepared
(1) prepare rat, be randomly divided into two groups, i.e. MSD groups and control group, 12 per group.
(2) after adaptability is fed 7 days, two groups give respectively gavage MSD liquid and distilled water, gavage amount：33.6g/
Kg.day, daily gavage twice, continuous gavage 7 days.
(3) 60min after last gavage, to rat abdominal aortic blood sampling is carried out.
(4) by the blood preparation of collection in being stored at room temperature 1h, 3000 × g centrifugation 20min.0.22 μm of membrane filtration, be placed in-
80 DEG C standby.The MSD groups of preparation and the serum of control group are respectively labeled as MSD-S groups and CONT-S groups.
(5) take above-mentioned MSD-S and CONT-S complete medium dilution, be diluted to 20%MSD-S, 40%MSD-S, 20%
CONT-S and 40%CONT-S.
(3) cell model is set up
(1) with complete medium culture THP-1 cell, condition of culture is 37 DEG C, 5%CO2。
(2) by THP-1 cells in good condition, by 1.0-1.5 × 106The concentration kind of/mL in 6 orifice plates, divide by 2mL/ holes
For two groups, M groups and N groups are respectively labeled as, wherein M groups are model group, and N groups are normal group.
(3) 2mL PMA (100ng/mL) are added to stimulate THP-1 cells in M groups and N group THP-1 cells so as to be divided into
Ripe macrophage.
(4) PMA stimulates after 3h, removes PMA.
(5) 2mL MSU solution (100 μ g/mL) is added in M group cells, 2mL complete mediums is added in N group cells.
(6) add the time of MSU to be labeled as 0h, in different time points cell supernatant, detection IL-1 β and TNF-α are collected
Secretion situation.Respectively at 3h, 6h, 15h, 24h collects cell supernatant, with IL-1 β in ELISA method detection cell supernatant
With the secretion situation of TNF-α.As a result as shown in Figure 1, 2.
Wherein Fig. 1 is the secretion situation of N group different time points IL-1 β and TNF-α.Fig. 2 is M group different time points IL-1 β
With the secretion situation of TNF-α.
(4) cell confirmatory experiment
(1) with complete medium culture THP-1 cell, condition of culture is 37 DEG C, 5%CO2。
(2) by THP-1 cells in good condition, by 1.0-1.5 × 106The concentration kind of/mL in 6 orifice plates, divide by 2mL/ holes
For six groups, 1,2,3,4,5,6 groups are respectively labeled as.
(3) add 200 μ L PMA (100ng/mL) to stimulate THP-1 cells in 1,2,3,4,5,6 groups of THP-1 cells, make
It is divided into the macrophage of maturation.
(4) PMA stimulates after 3h, removes PMA.Then according to following method, in each experimental group component is separately added into：
2mL complete mediums are added in 1 group of THP-1 cell；
To 2 groups of addition 1mL MSU solution (200 μ g/mL) and 1mL complete mediums (the final concentration of 100 μ g/mL of MSU)；
To 3 groups of addition 1mL MSU solution (200 μ g/mL) and 1mL 20%CONT-S (the final concentration of 100 μ g/mL of MSU,
CONT-S it is final concentration of 10%)；
To 4 groups of addition 1mL MSU solution (200 μ g/mL) and 1mL 40%CONT-S (the final concentration of 100 μ g/mL of MSU,
CONT-S it is final concentration of 20%)；
To 5 groups of addition 1mL MSU solution (200 μ g/mL) and 1mL 20%MSD-S (the final concentration of 100 μ g/mL of MSU,
MSD-S it is final concentration of 10%)；
To 6 groups of addition 1mL MSU solution (200 μ g/mL) and 1mL 40%MSD-S (the final concentration of 100 μ g/mL of MSU,
MSD-S it is final concentration of 20%).
For the more clear processing method to each group cell, now as shown in table 1 is summarized to the processing method of each group cell：
The each experimental group processing method contrast of table 1
| Group number | Processing method |
| 1 | PMA |
| 2 | PMA+MSU |
| 3 | PMA+MSU+10%CONT-S |
| 4 | PMA+MSU+20%CONT-S |
| 5 | PMA+MSU+10%MSD-S |
| 6 | PMA+MSU+20%MSD-S |
(5) add the time of MSU or MSU and MSD to be labeled as 0h, in post-stimulatory 24h cell supernatant is collected, use
The secretion situation of IL-1 β and TNF-α in ELISA method detection cell supernatant.As a result as shown in Figure 3,4.
(5) result and analysis
From Fig. 1,2, wherein 1 group is N groups, 2 groups is M groups, with 1 group (Fig. 1) contrast, is added in 2 groups (Fig. 2) after MSU,
With the prolongation of MSU stimulation times, the secretory volume of IL-1 β and TNF-α gradually increases in cell supernatant, and this meets gouty pass
The scorching patient's MSU crystal of section causes the situation that IL-1 β and TNF-α content rise in hydrops articuli, it was demonstrated that this confirmatory experiment is applied
Cell model be successfully established, can be used in treat urarthritis medicine research.
The cell model that this confirmatory experiment is set up, directly from the angle of cell, more traditional animal model, with more
Strong specific aim, can accurately judge MSU crystal to the monocytic impact that plays a major role in urarthritis and its
Inflammatory factor secretes situation.It is of the invention to be verified using the cell model, the Chinese medicine group of present invention offer can be accurately provided
The pharmacological action of compound and drug effect.
From the figure 3, it may be seen that comparing with 10%MSD-S groups with M groups, 10%CONT-S groups, 20%CONT-S groups, 20%MSD-S
The content of IL-1 β has significant decline in group cell supernatant.Prove that MSD can reduce the secretion of THP-1 cell IL-1 β, and
It is relevant with the concentration of MSD.Additionally, 20%MSD-S groups are close with the content of IL-1 β in N group cell supernatants, MSD energy is also indicated that
The secretion of THP-1 cell IL-1 β is enough reduced to normal level.
As shown in Figure 4, compare with 10%MSD-S groups with M groups, 10%CONT-S groups, 20%CONT-S groups, 20%MSD-S
The content of TNF-α significantly decreases in group cell supernatant.Prove that MSD can reduce the secretion of THP-1 cell TNF-αs, and
It is relevant with the concentration of MSD.Additionally, 20%MSD-S groups are close with the content of TNF-α in N group cell supernatants, MSD energy is also indicated that
The secretion of THP-1 cell TNF-αs is enough reduced to normal level.
Above confirmatory experiment shows that the Chinese medicine composition that the present invention is provided can effectively reduce being caused by the stimulation of MSU crystal
IL-1 β and TNF-α secretion increase.By using the cell model that this experiment is set up, this is explained from molecular level
The Chinese medicine composition of bright offer is for the treatment principle and therapeutic effect of urarthritis.
Additionally, the model that this experiment is set up, in 24h, the secretion situation of THP-1 cell IL-1 β and TNF-α has significantly
Rise, more meet the truth of acute gouty arthritis patient.Therefore, above experiment is it is also shown that in present invention offer
Drug composition, can there is effectively treatment acute gouty arthritis.
Additionally, inventor be also directed to the present invention offer Chinese medicine composition, carried out animal confirmatory experiment, be discussed in detail as
Under.
The animal confirmatory experiment of traditional Chinese medicine composition for treating urarthritis
(1) material and reagent
Rat：SPF level Wistar rats, male, 220-250g.Purchased from disease prevention and control center of Henan Province.
Uric acid sodium salt：Purchased from Sigma-Aldrich companies.
MSU crystalloid solutions：Weigh 8g uric acid sodium salts to be placed in 1600mL boiling water, with 1M NaOH pH 7.2 is adjusted to, heat
1.5h or so becomes to turbid solution and clarifies, and after room temperature cooling 24h is stood, and solid is put in evaporating dish 60 DEG C and is dried 24h after filtration, high
Temperature sterilizing, grinds standby.Facing the used time weighs appropriate deal, standby with the MSU crystalloid solutions that physiological saline is made into 20mg/mL.Institute
After testing rear endotoxin-free affects the MSU crystalloid solutions of configuration.
MSD liquids：The liquid of the Chinese medicine composition that the present invention is provided, decocts liquid, by liquid according to the mode of embodiment 1
Concentrated with Rotary Evaporators standby.
(2) rat urarthritis model is set up
After adaptability is fed 7 days, ball portion injects the MSU crystalloid solutions of 50 μ L 20mg/mL, left back foot to after Rat Right
Metacarpus injects the physiological saline of same volume, and 0h, 4h, 8h, 12h, 24h, 48h, the 72h after modeling, is surveyed with slide measure
The thickness of amount rat vola, with the arthritis that ball portion behind the right side and the ratio of left back ball portion thickness evaluate rat, experimental data
As shown in figure 5, ratio is considered as more than 1.1 successfully construct urarthritis model.
Fig. 5 shows that after injection MSU crystalloid solutions, rat foot has obvious swelling phenomenon, the 12h swelling journey after injection
Degree rises to maximum, is subsequently gradually lowered.Therefore, it is anti-with the rat vola inflammation of MSU crystalloid solutions (sodium salt of uric acid containing 1mg) stimulation
Should be urarthritis animal model.
(3) rat model confirmatory experiment
30 male SPF level rats are equally divided into into three groups：A groups, B groups and C groups, wherein A groups be pharmaceutical intervention group, B groups
For model group, C groups are normal group.Normal diet, drinking-water, after adaptability is fed 7 days, A group rats give 33.6g/kg.day
MSD liquid gavages, B groups rat and C groups rat give the physiological saline gavage of same volume, and daily gavage is twice, continuous to fill
Stomach 7 days, the 5th day of administration, the MSU crystalloid solutions for injecting 50 μ L 20mg/mL to A groups rat and B group rat hindlegs metacarpus were carried out
Modeling, C group rat hindlegs metacarpus injects the physiological saline of same volume, and 0h, 4h, 8h, 12h, 24h, the 48h after modeling,
72h, with the thickness of vernier caliper measurement rat vola, is commented with A groups rat or B groups rat with the ratio of C group rat vola thickness
The arthritis of valency rat.A groups rat and the ratio of C group rat vola thickness, and B groups rat is thick with C group rats vola
The ratio of degree, record is as shown in Figure 6.
As seen from Figure 6, the pretreated rat of Chinese medicine composition for providing through the present invention, to the big of MSU inductions
Mouse inflammation has obvious inhibitory action.Imply that the Chinese medicine composition of present invention offer can alleviate the pain induced by MSU crystal
Wind arthritis.
In order to contribute to preferably embodying the curative effect of the medicine that the present invention is provided, introduce such as in conjunction with specific clinical data
Under.
The clinical trial of the traditional Chinese medicine composition for treating urarthritis that the present invention is provided
Clinical data：Collect clinical urarthritis patient totally 189, the wherein male sex 103, women 86；Age
It is minimum 39 years old, it is maximum 72 years old；The course of disease is most short 3 months, most long 12 years；All cases have hyperuricemia.
Treatment method：The decoction prepared according to the method for embodiment 1 is taken, is within 14 days a course for the treatment of once a day, treat 4
Further consultation after the individual course for the treatment of.
Efficacy assessment standard：
Recovery from illness：Illness disappears, and blood uric acid is down to normal range (NR)；It is effective：Remission, blood uric acid reduces by 10%；It is invalid：Disease
Disease is unchanged, and Level of Serum Uric Acid is unchanged.
Therapeutic effect：
| Treatment number | Recovery from illness | It is effective | It is invalid |
| 189 | 145 | 39 | 5 |
Wherein, cure rate 76.7%, obvious effective rate 20.7%, inefficiency 2.6%, total effective rate 97.4%.
The Chinese medicine composition that the present invention is provided, can effectively treatment urarthritis, the total effective rate of clinical treatment reaches
97.4%.
Model case 1：Wang, man, 54 years old.Patient main suit's arthralgia 5 years, increases 2 days.Usually often feed meat or fish is greasy for patient
Product, then arthralgia outbreak.Examine and see that patient's finger and toe joint are red and swollen, pain with tenderness has at right hand middle finger interphalangeal joint
One scleroma, red tongue body, yellow and greasy fur, slippery and rapid pulse.Have a blood test 568 μm of ol/L of uric acid, and tentative diagnosis is acute gouty arthritis.It is dialectical
For：Insufficiency of natural endowment, endoretention of damp heat.The decoction prepared according to the method for embodiment 1 is taken, once a day, 14 days is a course for the treatment of, is controlled
Treat further consultation after 4 courses for the treatment of.Patient articular's pain symptom mitigates, and Level of Serum Uric Acid is reduced to normal level.
Model case 2：Zhang, man, 48 years old.Patient main suit's arthralgia 3 years, increases 1 day.Right sufficient Metatarsophalangeal joint
Pain, night-time attack bites sample in stinging, hurt like hell, with limitation of activity.Examine and see that the right sufficient Metatarsophalangeal joint of patient is red and swollen, Pi Wen
Height, tenderness, purplish tongue, yellow tongue fur is thick, and uneven pulse, sublingual vessel is dark reddish purple.Have a blood test 623 μm of ol/L of uric acid, the visible double track of joint ultrasound
Levy.Tentative diagnosis is acute gouty arthritis.It is dialectical to be:Endoretention of damp heat, stasis blocking train of thought.Take according to the method system of embodiment 1
Standby decoction, 14 days is a course for the treatment of once a day, and further consultation after 2 courses for the treatment of of treatment is added and subtracted to top.Patient pain's disease
Shape substantially mitigates, and Level of Serum Uric Acid is reduced to normal level.
By scientific compatibility, accurate validation, from a large amount of Chinese medicines, screening draws the Chinese traditional medicine composition of present invention offer to the present invention
Thing.The Chinese medicine composition that the present invention is provided is treated through the inspection of cell experiment, zoopery and clinical testing with clear and definite
The effect of urarthritis.
Finally it should be noted that：Various embodiments above only to illustrate technical scheme, rather than a limitation；To the greatest extent
Pipe has been described in detail with reference to foregoing embodiments to the present invention, it will be understood by those within the art that：Its according to
So the technical scheme described in foregoing embodiments can be modified, either which part or all technical characteristic are entered
Row equivalent；And these modifications or replacement, do not make the essence disengaging various embodiments of the present invention technology of appropriate technical solution
The scope of scheme.
Claims (10)
1. a kind of Chinese medicine composition for treating urarthritis, it is characterised in that the preparing raw material bag of the Chinese medicine composition
Include following component：
Rhizoma atractylodis, the bighead atractylodes rhizome, chinaroot greenbrier, Chinese yam, coix seed, radix achyranthis bidentatae, waras, reticulate millettia, the radix paeoniae rubrathe, oldenlandia diffusa, rheum officinale is yellow
Even, caulis lonicerae, plantain seed, semen brassicae, hawthorn, smilax and faenum graecum.
2. Chinese medicine composition according to claim 1, it is characterised in that in parts by weight, the Chinese medicine composition
Preparing raw material be made up of following component：
Rhizoma atractylodis 8-16 parts, bighead atractylodes rhizome 11-19 parts, chinaroot greenbrier 21-29 parts, Chinese yam 8-16 parts, coix seed 26-34 parts, radix achyranthis bidentatae 8-16 parts,
Waras 21-29 part, reticulate millettia 26-34 parts, radix paeoniae rubrathe 11-19 parts, oldenlandia diffusa 26-34 parts, rheum officinale 2-10 parts, coptis 8-16
Part, caulis lonicerae 16-24 parts, plantain seed 8-16 parts, semen brassicae 8-16 parts, hawthorn 8-16 parts, smilax 26-34 parts and faenum graecum
16-24 parts.
3. Chinese medicine composition according to claim 2, it is characterised in that in parts by weight, the Chinese medicine composition
Preparing raw material be made up of following component：
Rhizoma atractylodis 10-14 parts, bighead atractylodes rhizome 13-17 parts, chinaroot greenbrier 23-27 parts, Chinese yam 10-14 parts, coix seed 28-32 parts, radix achyranthis bidentatae 10-14
Part, waras 23-27 part, reticulate millettia 28-32 parts, radix paeoniae rubrathe 13-17 parts, oldenlandia diffusa 28-32 parts, rheum officinale 4-8 parts, the coptis
10-14 parts, caulis lonicerae 18-22 parts, plantain seed 10-14 parts, semen brassicae 10-14 parts, hawthorn 10-14 parts, smilax 28-32 parts with
And faenum graecum 18-22 parts.
4. Chinese medicine composition according to claim 3, it is characterised in that in parts by weight, the Chinese medicine composition
Preparing raw material be made up of following component：
12 parts of rhizoma atractylodis, 15 parts of the bighead atractylodes rhizome, 25 parts of chinaroot greenbrier, 12 parts of Chinese yam, 30 parts of coix seed, 12 parts of radix achyranthis bidentatae, 25 parts of waras, chicken blood
30 parts of rattan, 15 parts of the radix paeoniae rubrathe, 30 parts of oldenlandia diffusa, 6 parts of rheum officinale, 12 parts of the coptis, 20 parts of caulis lonicerae, 12 parts of plantain seed, semen brassicae
12 parts, 12 parts of hawthorn, 20 parts of 30 parts of smilax and faenum graecum.
5. application of the Chinese medicine composition described in any one of claim 1-4 in treatment urarthritis medicine is prepared.
6. application according to claim 5, it is characterised in that the urarthritis is acute gouty arthritis.
7. application according to claim 6, it is characterised in that the formulation of the treatment urarthritis medicine is soup
Agent.
8. application according to claim 7, it is characterised in that the occupation mode of the decoction is oral.
9. the application according to claim 7 or 8, it is characterised in that the preparation method of the decoction is：By the Chinese medicine group
The preparing raw material immersion of compound, subsequently decocts.
10. application according to claim 9, it is characterised in that the soak time is 30min, the decocting time is
1h。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710185916.2A CN106620435B (en) | 2017-03-24 | 2017-03-24 | Traditional Chinese medicine composition for treating gouty arthritis and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710185916.2A CN106620435B (en) | 2017-03-24 | 2017-03-24 | Traditional Chinese medicine composition for treating gouty arthritis and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106620435A true CN106620435A (en) | 2017-05-10 |
| CN106620435B CN106620435B (en) | 2019-12-20 |
Family
ID=58848590
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710185916.2A Active CN106620435B (en) | 2017-03-24 | 2017-03-24 | Traditional Chinese medicine composition for treating gouty arthritis and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106620435B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108578611A (en) * | 2018-07-16 | 2018-09-28 | 赵文萃 | Treat the compound Chinese medicinal preparation and preparation method thereof of gout |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101264215A (en) * | 2008-04-25 | 2008-09-17 | 北京中泰天和科技有限公司 | Medicinal composition for treating acute and chronic urarthritis and preparation thereof |
-
2017
- 2017-03-24 CN CN201710185916.2A patent/CN106620435B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101264215A (en) * | 2008-04-25 | 2008-09-17 | 北京中泰天和科技有限公司 | Medicinal composition for treating acute and chronic urarthritis and preparation thereof |
Non-Patent Citations (3)
| Title |
|---|
| 刘忠良: "中西医结合治疗痛风65例", 《河南中医》 * |
| 杨集群: "中医辨证治疗原发性痛风51例", 《吉林中医药》 * |
| 韩宏妮等: "痛风合剂治疗高尿酸血症及急性痛风性关节炎的实验研究", 《中国中医骨伤科杂志》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108578611A (en) * | 2018-07-16 | 2018-09-28 | 赵文萃 | Treat the compound Chinese medicinal preparation and preparation method thereof of gout |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106620435B (en) | 2019-12-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103893727B (en) | A kind of relieving pain and activating blood circulation relaxing muscles and tendons plaster and preparation method thereof | |
| CN103341004B (en) | Chinese medicine composition for treating delayed menstrual cycle | |
| CN103721045B (en) | For improving the Chinese traditional immunopoteniators of broiler immunologic function in growth course | |
| CN103463511B (en) | Traditional Chinese medicine composition for treating eczema | |
| CN104353047A (en) | Traditional Chinese medicine for treating nephritis | |
| CN102961648A (en) | Chinese herbal medicine compound preparation for treating advanced colorectal cancer | |
| CN103931846A (en) | Health care tea capable of reducing uric acid | |
| CN101406688B (en) | Compound formulation for treating rheumatic arthritis and rheumatoid arthritis | |
| CN104606560A (en) | Traditional-Chinese-medicine composition for treating stranguria | |
| CN101670058B (en) | Traditional Chinese medicine composition for treating gout | |
| CN109045229A (en) | The Chinese medicine composition and preparation method thereof for treating urarthritis | |
| CN102091311A (en) | Traditional Chinese medicinal composition for treating rheumatoid arthritis and preparation method thereof | |
| CN106215046A (en) | A kind of Chinese medicine treating acute gouty arthritis | |
| CN106620435A (en) | Traditional Chinese medicine composition for treating gouty arthritis and application thereof | |
| CN104096115A (en) | Traditional Chinese medicine composition for treating acute gouty arthritis | |
| CN102940816B (en) | Traditional Chinese medicine for treating gout | |
| CN105250620A (en) | Traditional Chinese medicine composition for treating chyluria | |
| CN101129584A (en) | Chinese medicine preparation for treating post partum hypogalactia | |
| CN104208640A (en) | Traditional Chinese medicine composition for treating delayed menstrual cycle | |
| CN103933408A (en) | Traditional Chinese medicinal decoction for treating acute gouty arthritis | |
| CN107715084A (en) | A kind of Chinese medicine preparation for treating irregular menstruation and preparation method thereof | |
| CN103211949B (en) | Traditional Chinese medicine composition for treating gastric diseases of human body as well as preparation method and application thereof | |
| CN104306694B (en) | A kind of Chinese medicine composition preparation method and medical usage for treating gout | |
| CN102188643A (en) | Medicament for treating damp-heat blockage syndrome and its preparation method | |
| CN101757379A (en) | Traditional Chinese medicine formula for treating female pelvic inflammation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20200115 Address after: 450052 Construction No. 50 East Road, 27 District, Henan, Zhengzhou Patentee after: First Affiliated Hospital of Zhengzhou University Address before: Ruzhou City, Pingdingshan City, Henan province 450000 Yang Lou Xiang Ma Zhuang 6 groups Patentee before: Liu Yafei |
|
| TR01 | Transfer of patent right |